New pill could tame skin lupus flares

NCT ID NCT07440537

Recruiting now Disease control Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an oral medication called ICP-488 for people with cutaneous lupus erythematosus (CLE), a condition that causes painful skin rashes and lesions. About 105 adults aged 18–75 with moderate-to-severe CLE will receive either the drug or a placebo for 16 weeks. The main goal is to see if the drug reduces skin disease severity and is safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous lupus erythematosus discoid lupus erythematosus subacute cutaneous lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)

Contacts and locations

Locations

Affiliated Drum Tower Hospital, Medical School of Nanjing University
NOT_YET_RECRUITING

Nanjing, Jiangsu, 210008, China
Chongqing Hospital of Traditional Chinese Medicine
NOT_YET_RECRUITING

Chongqing, Chongqing Municipality, 400021, China
Dermatology Hospital of Jiangxi Province
RECRUITING

Nanchang, Jiangxi, 330000, China
Dermatology Hospital of Shandong First Medical University
RECRUITING

Jinan, Shandong, 250022, China
Dermatology Hospital of Southern Medical University
RECRUITING

Guangzhou, Guangdong, 510091, China
Dongguan people's hospital
RECRUITING

Dongguan, Guangdong, 523059, China
First Hospital of Shanxi Medical University
NOT_YET_RECRUITING

Taiyuan, Shanxi, 030001, China
Hangzhou Third people's Hospital
NOT_YET_RECRUITING

Hangzhou, Zhejiang, 310009, China
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College
NOT_YET_RECRUITING

Nanjing, Jiangsu, Qianjin Lu, China
Huashan Hospital Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200040, China
Jinan Central Hospital
RECRUITING

Jinan, Shandong, 250013, China
Jingzhou Central Hospital
NOT_YET_RECRUITING

Jingzhou, Hubei, 434020, China
Peking University First Hospital
RECRUITING

Beijing, Beijing Municipality, 100034, China
People's Hospital of Xinjiang Uygur Autonomous Region
NOT_YET_RECRUITING

Ürümqi, Xinjiang Uygur Autonomous Region, 830001, China
Shanghai Skin Disease Hospital
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200443, China
Sichuan Provincial People's Hospital
NOT_YET_RECRUITING

Chengdu, Sichuan, 610072, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, 510120, China
The First Affiliated Hospital of Anhui Medical University
NOT_YET_RECRUITING

Hefei, Anhui, 230022, China
The First Affiliated Hospital of Chongqing Medical University
NOT_YET_RECRUITING

Chongqing, Chongqing Municipality, 400010, China
The First Affiliated Hospital of Fujian Medical University
NOT_YET_RECRUITING

Fuzhou, Fujian, 350005, China
The First Affiliated Hospital of Kunming Medical University
RECRUITING

Kunming, Yunnan, 650032, China
The First Affiliated Hospital of Zhengzhou University
NOT_YET_RECRUITING

Zhengzhou, Henan, 450052, China
The First AffiliatedHospital of China Medical University
NOT_YET_RECRUITING

Shenyang, Liaoning, 110001, China
The Second Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, 215004, China
The Second Hospital of Hebei Medical University
NOT_YET_RECRUITING

Shijiazhuang, Hebei, China
West China Hospital, Sichuan University
NOT_YET_RECRUITING

Chengdu, Sichuan, 610041, China
Xuanwu Hospital Capital Medical University
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100053, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.